Allianz Asset Management’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$158M Sell
1,968,211
-224,059
-10% -$18.5M 0.17% 118
2025
Q4
$187M Buy
2,192,270
+443,285
+25% +$36.4M 0.19% 93
2025
Q3
$136M Buy
1,748,985
+998,853
+133% +$78M 0.15% 126
2025
Q2
$58.7M Buy
750,132
+290,048
+63% +$21.6M 0.07% 277
2025
Q1
$33.3M Buy
460,084
+6,436
+1% +$461K 0.04% 416
2024
Q4
$33.6M Sell
453,648
-60,073
-12% -$4.2M 0.04% 404
2024
Q3
$33.9M Buy
513,721
+42,404
+9% +$3.08M 0.05% 383
2024
Q2
$43.5M Sell
471,317
-66,357
-12% -$5.88M 0.06% 298
2024
Q1
$51.4M Sell
537,674
-215,901
-29% -$18.1M 0.08% 254
2023
Q4
$57.5M Sell
753,575
-271,516
-26% -$18.9M 0.09% 213
2023
Q3
$71M Sell
1,025,091
-204,237
-17% -$16.4M 0.12% 184
2023
Q2
$116M Sell
1,229,328
-8,441
-0.7% -$734K 0.21% 102
2023
Q1
$102M Sell
1,237,769
-40,208
-3% -$3.16M 0.18% 110
2022
Q4
$95.3M Buy
1,277,977
+31,308
+3% +$2.41M 0.19% 115
2022
Q3
$103M Sell
1,246,669
-113,986
-8% -$11M 0.21% 98
2022
Q2
$129M Buy
1,360,655
+214,039
+19% +$22.2M 0.12% 181
2022
Q1
$135M Sell
1,146,616
-330,250
-22% -$37M 0.1% 215
2021
Q4
$191M Buy
1,476,866
+31,676
+2% +$3.69M 0.13% 172
2021
Q3
$164M Buy
1,445,190
+529,784
+58% +$60.5M 0.13% 172
2021
Q2
$94.8M Buy
915,406
+111,990
+14% +$10.6M 0.08% 243
2021
Q1
$67.2M Sell
803,416
-226,020
-22% -$19.1M 0.07% 294
2020
Q4
$93.9M Buy
1,029,436
+294,332
+40% +$24.4M 0.09% 216
2020
Q3
$58.7M Sell
735,104
-57,081
-7% -$4.45M 0.07% 294
2020
Q2
$54.7M Sell
792,185
-24,349
-3% -$1.73M 0.06% 319
2020
Q1
$51.3M Buy
816,534
+258,933
+46% +$18.7M 0.07% 305
2019
Q4
$43.4M Buy
557,601
+179,886
+48% +$14M 0.04% 480
2019
Q3
$27.7M Buy
377,715
+28,512
+8% +$2M 0.03% 645
2019
Q2
$21.5M Sell
349,203
-104,436
-23% -$6.32M 0.02% 780
2019
Q1
$28.9M Sell
453,639
-16,953
-4% -$967K 0.03% 610
2018
Q4
$24M Buy
470,592
+10,311
+2% +$522K 0.03% 620
2018
Q3
$26.7M Sell
460,281
-35,946
-7% -$1.76M 0.02% 726
2018
Q2
$24.1M Buy
496,227
+108,111
+28% +$5.05M 0.02% 773
2018
Q1
$18.1M Buy
388,116
+258,696
+200% +$11.2M 0.02% 943
2017
Q4
$4.86M Sell
129,420
-1,363,911
-91% -$50.1M ﹤0.01% 1636
2017
Q3
$54.4M Sell
1,493,331
-369,177
-20% -$14.1M 0.05% 473
2017
Q2
$73.4M Sell
1,862,508
-172,575
-8% -$6.3M 0.07% 334
2017
Q1
$63.8M Sell
2,035,083
-870,771
-30% -$27.3M 0.06% 387
2016
Q4
$90.8M Buy
2,905,854
+336,018
+13% +$10.9M 0.08% 304
2016
Q3
$103M Sell
2,569,836
-67,392
-3% -$2.54M 0.1% 215
2016
Q2
$87.7M Sell
2,637,228
-315,900
-11% -$10.8M 0.09% 239
2016
Q1
$86.8M Buy
2,953,128
+2,347,122
+387% +$64.8M 0.1% 200
2015
Q4
$16M Sell
606,006
-77,352
-11% -$2.01M 0.02% 859
2015
Q3
$16.2M Buy
683,358
+32,916
+5% +$794K 0.02% 793
2015
Q2
$15.4M Buy
650,442
+490,140
+306% +$11.1M 0.02% 905
2015
Q1
$3.81M Buy
160,302
+56,220
+54% +$1.26M ﹤0.01% 1326
2014
Q4
$2.21M Buy
104,082
+24
+0% +$482 ﹤0.01% 1512
2014
Q3
$1.77M Buy
104,058
+17,310
+20% +$273K ﹤0.01% 1477
2014
Q2
$1.24M Sell
86,748
-2,448,738
-97% -$33.2M ﹤0.01% 1336
2014
Q1
$31.3M Sell
2,535,486
-1,218,636
-32% -$14.1M 0.04% 442
2013
Q4
$41.1M Buy
3,754,122
+2,413,212
+180% +$27.2M 0.05% 376
2013
Q3
$15.6M Buy
1,340,910
+63,510
+5% +$743K 0.02% 564
2013
Q2
$14.3M Buy
+1,277,400
New +$15.1M 0.02% 557

Other funds holding EW

Allianz Asset Management's EW Position: Q1 2026 in Review

Allianz Asset Management reduced its Edwards Lifesciences (EW) stake by 10% in Q1 2026, selling an estimated $18.5M and leaving 1,968,211 shares worth $158M. The position accounts for 0.17% of the portfolio, ranked #118.

Allianz Asset Management first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $191M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Allianz Asset Management held 1,968,211 shares of Edwards Lifesciences worth $158M as of Q1 2026.
  • Allianz Asset Management sold 224,059 Edwards Lifesciences shares in Q1 2026, an estimated $18.5M.
  • Edwards Lifesciences made up 0.17% of Allianz Asset Management's portfolio in Q1 2026, its #118 holding.
  • Allianz Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Allianz Asset Management's Edwards Lifesciences position peaked at $191M in Q4 2021.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.